

Stephan Winnik

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3006834/publications.pdf>

Version: 2024-02-01

30
papers

1,479
citations

623574

14
h-index

477173

29
g-index

30
all docs

30
docs citations

30
times ranked

2910
citing authors

#	ARTICLE	IF	CITATIONS
1	Right ventricular only pacing for cardiac resynchronization therapy. <i>Europace</i> , 2022, 24, 70-71.	0.7	2
2	Transesophageal Echocardiography-Guided Transseptal Left Atrial Access to Improve Safety in Patients Undergoing Pulmonary Vein Isolation. <i>Journal of Clinical Medicine</i> , 2022, 11, 2546.	1.0	4
3	Takotsubo Syndrome in Coronavirus Disease 2019. <i>American Journal of Cardiology</i> , 2021, 138, 118-120.	0.7	9
4	Transvenous lead extraction in a patient with persistent left superior vena cava. <i>HeartRhythm Case Reports</i> , 2021, 7, 153-156.	0.2	3
5	Guidance on the management of left ventricular assist device (LVAD) supported patients for the non-LVAD specialist healthcare provider: executive summary. <i>European Journal of Heart Failure</i> , 2021, 23, 1597-1609.	2.9	20
6	Heart Failure Association of the European Society of Cardiology position paper on the management of left ventricular assist device-supported patients for the non-left ventricular assist device specialist healthcare provider: Part 2: at the emergency department. <i>ESC Heart Failure</i> , 2021, 8, 4409-4424.	1.4	7
7	Heart failure in COVID-19: the multicentre, multinational PCHF-COVICAV registry. <i>ESC Heart Failure</i> , 2021, 8, 4955-4967.	1.4	26
8	HFA of the ESC Position paper on the management of LVAD supported patients for the non LVAD specialist healthcare provider Part 1: Introduction and at the non-hospital settings in the community. <i>ESC Heart Failure</i> , 2021, 8, 4394-4408.	1.4	5
9	Long-term follow-up after cardiac resynchronization therapy-optimization in a real-world setting: A single-center cohort study. <i>Cardiology Journal</i> , 2021, 28, 728-737.	0.5	2
10	HFA of the ESC position paper on the management of LVAD-supported patients for the non-LVAD specialist healthcare provider Part 3: at the hospital and discharge. <i>ESC Heart Failure</i> , 2021, 8, 4425-4443.	1.4	10
11	Treatment of Advanced Heart Failure—Focus on Transplantation and Durable Mechanical Circulatory Support. <i>Heart Failure Clinics</i> , 2021, 17, 697-708.	1.0	2
12	Differential effect of cardiac resynchronization therapy in patients with diabetes mellitus: a long-term retrospective cohort study. <i>ESC Heart Failure</i> , 2020, 7, 2773-2783.	1.4	4
13	Pulsatile arterial blood pressure mimicking aortic valve opening during continuous-flow LVAD support: a case report. <i>Journal of Cardiothoracic Surgery</i> , 2019, 14, 219.	0.4	4
14	Right Ventricular Failure: Pathophysiology, Diagnosis and Treatment. <i>Cardiac Failure Review</i> , 2019, 5, 140-146.	1.2	85
15	Usefulness of a clinical risk score to predict the response to cardiac resynchronization therapy. <i>International Journal of Cardiology</i> , 2018, 260, 82-87.	0.8	20
16	Loss of Sirt3 accelerates arterial thrombosis by increasing formation of neutrophil extracellular traps and plasma tissue factor activity. <i>Cardiovascular Research</i> , 2018, 114, 1178-1188.	1.8	44
17	The effect of oxygen in Sirt3-mediated myocardial protection: a proof-of-concept study in cultured cardiomyoblasts. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 102-112.	1.0	0
18	Brain-derived neurotrophic factor Val66Met polymorphism in depression and thrombosis: SIRT1 as a possible mediator. <i>European Heart Journal</i> , 2017, 38, ehv692.	1.0	10

#	ARTICLE	IF	CITATIONS
19	"Real world" experience in Cardiac Resynchronization Therapy at a Swiss Tertiary Care Center. Swiss Medical Weekly, 2017, 147, w14425.	0.8	2
20	Mild endothelial dysfunction in Sirt3 knockout mice fed a high-cholesterol diet: protective role of a novel C/EBP- β -dependent feedback regulation of SOD2. Basic Research in Cardiology, 2016, 111, 33.	2.5	28
21	The Sirt1 activator SRT3025 provides atheroprotection in ApoE ^{-/-} mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression. European Heart Journal, 2015, 36, 51-59.	1.0	117
22	Protective effects of sirtuins in cardiovascular diseases: from bench to bedside. European Heart Journal, 2015, 36, 3404-3412.	1.0	354
23	Deletion of Sirt3 does not affect atherosclerosis but accelerates weight gain and impairs rapid metabolic adaptation in LDL receptor knockout mice: implications for cardiovascular risk factor development. Basic Research in Cardiology, 2014, 109, 399.	2.5	54
24	The wealth of nations and the dissemination of cardiovascular research. International Journal of Cardiology, 2013, 169, 190-195.	0.8	7
25	Systemic VEGF inhibition accelerates experimental atherosclerosis and disrupts endothelial homeostasis – implications for cardiovascular safety. International Journal of Cardiology, 2013, 168, 2453-2461.	0.8	86
26	Abnormal High-Density Lipoprotein Induces Endothelial Dysfunction via Activation of Toll-like Receptor-2. Immunity, 2013, 38, 754-768.	6.6	261
27	Endothelial mineralocorticoid receptor activation mediates endothelial dysfunction in diet-induced obesity. European Heart Journal, 2013, 34, 3515-3524.	1.0	132
28	From abstract to impact in cardiovascular research: factors predicting publication and citation. European Heart Journal, 2012, 33, 3034-3045.	1.0	66
29	SIRT1 – An Anti-Inflammatory Pathway at the Crossroads Between Metabolic Disease and Atherosclerosis. Current Vascular Pharmacology, 2012, 10, 693-696.	0.8	59
30	Dietary ω -3 linolenic acid diminishes experimental atherogenesis and restricts T cell-driven inflammation. European Heart Journal, 2011, 32, 2573-2584.	1.0	56